#orforglipron

Alternativa Ozempic senza iniezioni: il confronto completo (2026)

Análise Filtro-Rx®: Foundayo® (orforglipron, Eli Lilly) — o que a aprovação recorde da FDA muda no…

Primeira pílula GLP-1 não-peptídica aprovada no mundo. Cinquenta dias entre submissão e aprovação. Sem restrição alimentar. Quatro pontos…

Sete medicamentos GLP-1, oito anos e meio, três continentes: a cronologia completa de Ozempic a…

Análise técnica independente sobre Ozempic, Wegovy, Mounjaro, Poviztra, Foundayo (orforglipron), Ozivy e Retatrutida — datas oficiais…

Which Weight-Loss Drug Is Right for You? A Biostatistician Explains What the Studies Really Mean

Over the last few years, weight-loss medicine has transformed from a niche treatment area into one of the biggest changes in modern…

A Comprehensive Analysis of Orforglipron Clinical Trials in Type 2 Diabetes (ACHIEVE Program)

On April 1, 2026, the U.S. Food and Drug Administration officially approved Eli Lilly’s novel oral weight-loss drug, Founday…

The Pill That Threatens Ozempic’s Dominance

The Weight Loss Drug That Could Kill Injections

Lilly’s Oral GLP-1 Breakthrough Reshapes Obesity Drug Market as Novo Nordisk Faces New Rival

Lilly’s oral GLP-1 orforglipron shows strong Phase 3 results, shaking up the obesity drug market and challenging Novo Nordisk.

Orforglipron — the weight-loss pill that imitates nature

Imagine that you can have Ozempic in your pill box. No refrigeration, no injection, just your breakfast drink with your weight-loss pill…